EEF2K and bladder transitional cell carcinoma: Likewise, disease-free survival (DFS) analysis data showed (Fig. 3B, Table 1) that low expression of eEF2K was associated with poorer DFS in BLCA (p = 0.0074), and high expression of eEF2K was correlated with poorer DFS prognosis in CHOL (p = 0.036), ESCA (p = 0.04), HNSC (p = 0.042), and UCEC (p = 0.019).